Conmed (CNMD) | Financial Analysis & Statements
Conmed Corporation Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
373.2M
Gross Profit
218.3M
58.49%
Operating Income
36.6M
9.81%
Net Income
16.7M
4.49%
EPS (Diluted)
$0.54
Balance Sheet Metrics
Total Assets
2.3B
Total Liabilities
1.3B
Shareholders Equity
1.0B
Debt to Equity
1.25
Cash Flow Metrics
Operating Cash Flow
41.0M
Free Cash Flow
41.2M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Conmed Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.4B | 1.3B | 1.2B | 1.0B | 1.0B |
| Cost of Goods Sold | 624.2M | 574.0M | 568.5M | 474.2M | 442.6M |
| Gross Profit | 750.5M | 733.0M | 676.2M | 571.2M | 568.0M |
| Gross Margin % | 54.6% | 56.1% | 54.3% | 54.6% | 56.2% |
| Operating Expenses | |||||
| Research & Development | 55.9M | 54.4M | 52.6M | 47.2M | 43.6M |
| Selling, General & Administrative | 592.0M | 478.3M | 503.0M | 454.0M | 414.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 647.9M | 532.7M | 555.6M | 501.2M | 458.3M |
| Operating Income | 102.6M | 200.3M | 120.6M | 70.1M | 109.7M |
| Operating Margin % | 7.5% | 15.3% | 9.7% | 6.7% | 10.9% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 31.1M | 37.3M | 39.8M | 28.9M | 35.5M |
| Other Non-Operating Income | -418.0K | - | - | -112.0M | -1.1M |
| Pre-tax Income | 71.1M | 163.0M | 80.8M | -70.9M | 73.1M |
| Income Tax | 24.1M | 30.6M | 16.4M | 9.7M | 10.6M |
| Effective Tax Rate % | 33.8% | 18.8% | 20.3% | 0.0% | 14.4% |
| Net Income | 47.1M | 132.4M | 64.5M | -80.6M | 62.5M |
| Net Margin % | 3.4% | 10.1% | 5.2% | -7.7% | 6.2% |
| Key Metrics | |||||
| EBITDA | 176.5M | 272.2M | 192.5M | 27.6M | 179.3M |
| EPS (Basic) | $1.52 | $4.29 | $2.10 | $-2.68 | $2.14 |
| EPS (Diluted) | $1.51 | $4.25 | $2.04 | $-2.68 | $1.94 |
| Basic Shares Outstanding | 31036000 | 30846000 | 30668000 | 30040000 | 29162000 |
| Diluted Shares Outstanding | 31036000 | 30846000 | 30668000 | 30040000 | 29162000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Conmed Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 40.8M | 24.5M | 24.3M | 28.9M | 20.8M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 247.8M | 237.7M | 242.3M | 191.3M | 183.9M |
| Inventory | 355.5M | 346.7M | 318.3M | 332.3M | 231.6M |
| Other Current Assets | 28.7M | 31.1M | 30.8M | 28.6M | 23.8M |
| Total Current Assets | 672.9M | 640.0M | 615.6M | 581.2M | 460.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 2.2B | 2.2B | 2.3B | 2.3B | 1.7B |
| Intangible Assets | 582.1M | 617.7M | 649.5M | 681.8M | 471.0M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 150.5M | 127.4M | 107.3M | 103.5M | 108.5M |
| Total Non-Current Assets | 1.7B | 1.7B | 1.7B | 1.7B | 1.3B |
| Total Assets | 2.3B | 2.3B | 2.3B | 2.3B | 1.8B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 93.6M | 102.2M | 88.2M | 73.4M | 58.2M |
| Short-term Debt | 712.0K | 715.0K | 708.0K | 69.7M | 12.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 138.5M | 109.8M | 151.7M | 98.7M | 65.7M |
| Total Current Liabilities | 315.0M | 278.1M | 310.7M | 296.6M | 196.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 834.2M | 905.1M | 973.1M | 985.1M | 672.4M |
| Deferred Tax Liabilities | 79.5M | 74.1M | 60.9M | 66.7M | 68.5M |
| Other Non-Current Liabilities | 63.9M | 86.3M | 121.0M | 203.7M | 43.0M |
| Total Non-Current Liabilities | 977.6M | 1.1B | 1.2B | 1.3B | 783.9M |
| Total Liabilities | 1.3B | 1.3B | 1.5B | 1.6B | 980.6M |
| Equity | |||||
| Common Stock | 313.0K | 313.0K | 313.0K | 313.0K | 313.0K |
| Retained Earnings | 588.8M | 560.3M | 452.5M | 412.6M | 496.6M |
| Treasury Stock | 12.9M | 15.6M | 15.0M | 22.8M | 54.1M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.0B | 962.7M | 834.2M | 745.5M | 785.4M |
| Key Metrics | |||||
| Total Debt | 834.9M | 905.8M | 973.8M | 1.1B | 684.7M |
| Working Capital | 357.8M | 361.9M | 304.9M | 284.7M | 263.5M |
Balance Sheet Composition
Conmed Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 47.1M | 132.4M | 64.5M | -80.6M | 62.5M |
| Depreciation & Amortization | 74.3M | 71.9M | 71.9M | 69.5M | 70.7M |
| Stock-Based Compensation | 28.3M | 25.6M | 24.3M | 21.7M | 16.3M |
| Working Capital Changes | -26.4M | -39.7M | -39.6M | -90.7M | -55.7M |
| Operating Cash Flow | 155.4M | 167.0M | 125.3M | 24.5M | 110.9M |
| Investing Activities | |||||
| Capital Expenditures | -19.8M | -13.1M | -19.0M | -21.8M | -14.9M |
| Acquisitions | - | 0 | 0 | -227.7M | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -21.0M | -13.1M | -20.0M | -249.5M | -14.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -24.7M | -24.7M | -24.5M | -24.0M | -23.3M |
| Debt Issuance | 720.7M | 751.0M | 692.0M | 1.3B | 379.2M |
| Debt Repayment | -795.3M | -823.0M | -780.0M | -898.0M | -460.4M |
| Financing Cash Flow | -135.8M | -151.0M | -110.4M | 222.5M | -168.5M |
| Free Cash Flow | 150.9M | 153.9M | 106.3M | 11.6M | 96.9M |
| Net Change in Cash | -1.4M | 2.9M | -5.1M | -2.5M | -72.5M |
Cash Flow Trend
Conmed Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
25.39
Forward P/E
7.78
Price to Book
1.15
Price to Sales
0.86
PEG Ratio
-0.50
Profitability Ratios
Profit Margin
3.42%
Operating Margin
7.25%
Return on Equity
4.72%
Return on Assets
3.47%
Financial Health
Current Ratio
2.14
Debt to Equity
85.91
Beta
0.99
Per Share Data
EPS (TTM)
$1.51
Book Value per Share
$33.36
Revenue per Share
$44.29
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CNMD | 1.2B | 25.39 | 1.15 | 4.72% | 3.42% | 85.91 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Axogen | 1.9B | -110.18 | 13.15 | -13.49% | -6.97% | 55.50 |
| Establishment Labs | 1.9B | -37.89 | 79.68 | -133.25% | -24.19% | 1,123.15 |
| Artivion | 1.8B | 179.71 | 4.03 | 2.70% | 2.21% | 57.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.






